List view / Grid view

Benjamin Moutier (Senior Vice President of Vaccines and Immune Therapies - AstraZeneca)

 

article

New fixed-duration therapy could reshape CLL care

Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY…

28 May 2025 | By

Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment…